Incyte (INCY) Q2 2025 10-Q Quarterly Report
Filed: Jul 29, 2025Period ending Jun 30, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR Incyte (INCY) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 29, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Incyte Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1,215.5M Q2 2025, up 16.4% YoY from $1,043.8M Q2 2024; 6-month revenue $2,268.4M up 17.9% YoY
- • Net income $405.0M Q2 2025 vs loss $444.6M Q2 2024; operating expenses R&D $494.9M Q2 2025 vs $1,138.4M Q2 2024
Incyte Q2 2025 Quarterly FinancialsXBRL
Revenue
$1.2B
▲ +16.5% YoY▲ +15.4% QoQ
Net Income
$405M
▲ +191.1% YoY▲ +156.0% QoQ
Operating Margin
43.6%
▲ +8944bp YoY▲ +2414bp QoQ
Net Margin
33.3%
▲ +7591bp YoY▲ +1829bp QoQ
EPS (Diluted)
$2.04
▲ +202.5% YoY▲ +155.0% QoQ
Operating Cash Flow
$45M
▲ +107.8% YoY▼ -83.2% QoQ
Source: XBRL data from Incyte Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Incyte Quarterly Reports
Get deeper insights on Incyte
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.